The In Vitro Biotransformation of the Fusion Protein Tetranection-Apolipoprotein A1

Simone Schadt1, Christophe Husser2, Roland F. Staack2, Aynur Ekciler1, Na Hong Qiu1, Stephen Fowler1, Christoph Funk1 & Nicole A. Kratochwil1

As more and more protein biotherapeutics enter the drug discovery pipelines, there is an increasing interest in tools for mechanistic drug metabolism investigations of biologics in order to identify and prioritize the most promising candidates. Understanding or even predicting the in vivo clearance of biologics and to support translational pharmacokinetic modeling activities is essential, however there is a lack of effective and validated in vitro cellular tools. Although different mechanisms have to be addressed in the context of biologics disposition, the scope is not comparable to the nowadays widely established tools for early characterization of small molecule disposition. Here, we describe a biotransformation study of the fusion protein tetranection apolipoprotein A1 by cellular systems. The in vivo biotransformation of tetranection apolipoprotein A1 has been described previously, and the same major biotransformation product could also be detected in vitro, by a targeted and highly sensitive detection method based on chymotrypsin digest. In addition, the protease responsible for the formation of this biotransformation product could be elucidated to be DPP4. To our knowledge, this is one of the first reports of an in vitro biotransformation study by cells of a therapeutic protein.
While a number of reports on in vitro biotransformation studies of GIP, GLP-1, and other peptides exist\textsuperscript{13–15}, to date, there are only few, if any, reports on the in vitro biotransformation of therapeutic proteins using cellular systems. In this article, we describe the investigation and application of in vitro cellular systems for the biotransformation of the therapeutic fusion protein tetranectin-apolipoprotein A1 (TN-ApoA1). This molecule is composed of a portion of human apolipoprotein A1 (ApoA1) and tetranectin (TN). The in vivo biotransformation of lipidated TN-ApoA1 has been described previously\textsuperscript{16}. The formation of the major catabolite [3-285] of TN-ApoA1, generated by cleavage of AP at the N-terminus of the sequence, was fast and complete in vivo within 24 h after intravenous administration of TN-ApoA1 to rabbits and also in Cynomolgus monkeys and rats.

Experimental Section

Reference compounds. Lipidated TN-ApoA1 was prepared as follows: TN-ApoA1 was lipidated with pure POPC/DPPC (3/1; w/w) in a protein to lipid ratio of 1/60. POPC: Palmitoyl oleoyl phosphatidylcholine; DPPC: Dipalmitoyl phosphatidylcholine. The stock solution of lipidated TN-ApoA1 (10 mg/mL) was prepared by dissolving the appropriate amount in aqueous solution of 250 mM TRIS buffer (pH 7.5), 10 mM methionine and 140 mM NaCl. The purity of TN-ApoA1 was >85%. The amino acid sequence of TN-ApoA1 is as follows: APIVNAKKDVVNTKMF and IVNAKKDVVNTKMF.

Chymotrypsin smart digest kit were purchased from Thermo Fisher Scientific (Rheinach, Switzerland), as well as F. Hoffmann-La Roche Ltd. (Basel, Switzerland). 2,2,2-Trifluoroacetic acid (TFA) (purity 99.5%), Gibco fetal calf serum (FCS), Gibco DBS buffer (pH 7.2), Pierce magnetic beads coated with streptavidin (10 mg/mL) and Chymotrypsin smart digest kit were purchased from Thermo Fisher Scientific (Rheinach, Switzerland), as well as the custom-synthesized reference peptides APIVNAKKDVVNTKMF and IVNAKKDVVNTKMF.

Incubation of TN-ApoA1 with DPP4. Biotransformation of TN-ApoA1 with DPP4 was assayed in 0.5 mL Protein LoBind tubes at 37°C. 6.1 µg TN-ApoA1 with incubated with 1 µg/µL recombinant DPP4 in DBS buffer pH 7.2 with a total reaction volume of 100.0 µL. At time points 0, 30, 60 and 120 min, 10 µL of incubation solution was removed and mixed with 40 µL 0.1% TFA/TFEtOH 95/5 and analysed.

Incubation of TN-ApoA1 with RPTEC/TERT1 cells and primary HUVEC cells. Primary Renal Proximal Tubule Epithelial Cells immortalized using the telomerase reverse transcriptase (RPTEC/TERT1) were cultivated in DMEM-Ham’s F-12 (1:1) media supplemented with 2% FCS, 4 mM L-glutamine, 10 mM HEPES buffer, 5 mM triiodothyronine, 10 ng/mL recombinant human EGF, 3.5 g/mL ascorbic acid, 25 µg/mL of TN-ApoA1. The cell density was 10³ cells/well. The cells were incubated with 5.0, 4, 24, 48 hrs at 37°C and 5% CO₂. The final incubation samples were stored at −80°C for the subsequent LC-MS/MS analysis.

Enzyme incubations. DPP4 enzymatic activity was assayed in a 96-well plate at 37°C. 25 µM substrate Gly-Pro-AMC was mixed with 75 ng/mL recombinant DPP4 or 20 µg cell lysate in 50 mM Tris–HCl buffer pH 8.2 with total reaction volume of 200.0 µL. 2 µM Sitagliptin was used as DPP4 specific inhibitor. DPP4 activity was determined kinetically by measuring the velocities of AMC release from the substrate at excitation and emission wavelengths of 380 nm and 460 nm with a fluorescence microplate reader (Molecular Devices, San Jose, USA) set 0.25 minute as time interval\textsuperscript{17}.

Enzymatic digest with Chymotrypsin. Enzymatic digest with chymotrypsin was conducted with the SMART Digest Kit Chymotrypsin according to the user manual. In short, 50 µL sample in Tris Buffer was transferred to a PCR tube containing the SMART Digest standard resin slurry and 150 µL digest buffer. Digestion was
conducted in a heated shaker at 1100 rpm at 70 °C for 40 min. To stop the digestion, the tubes were centrifuged and 5 μL of the supernatant were directly injected into the HPLC system.

**LC-MS instrumentation.** A Thermo Scientific Dionex UltiMate NCP-3200RS Binary Rapid Separation HPLC system was used in combination with a Pal autosampler (CTC Analytics AG, Zwingen, Switzerland) and a Thermo Scientific Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Scientific, Bremen, Germany) equipped with an electrospray ionization (ESI) source. The components of the UltiMate system were specifically designed for operating at pressures up to 800 bar.

**Chromatographic separation of intact proteins.** The isolated protein fraction was analyzed on a monolithic HPLC column ProSwift RP from Thermo Fisher Scientific (Reinach, Switzerland), 200 μm i.d. x 250 mm, at a flow rate of 10 μL/min. Mobile Phase A consisted of 0.1% aqueous formic acid, and mobile Phase B of 0.1% aqueous formic acid/acetonitrile 5/95. At the start of the linear gradient, eluent B was kept at 5% for 2 min and then raised to 95% within 14 min and maintained for 2 min, and then decreased again to 5% for re-equilibration of the column.

**Chromatographic separation of peptides from digest with chymotrypsin.** A 5 μL aliquot of the sample following solid phase extraction was injected onto the analytical column by gradient elution at a flow rate of 10 μL/min. At the start of the linear gradient, eluent B was kept at 2% for 2 min and then raised to 45% within 30 min. Thereafter, eluent B was increased to 95% and maintained for 3 min, and then decreased again to 2% for re-equilibration of the column. The trapping column and the analytical column were kept at 70 °C during the whole analysis sequence.

**Results**

The major in vivo biotransformation product of TN-ApoA1 is formed by cleavage of AP from the N-terminus. In this study, formation of the major catabolite [3-285] of TN-ApoA1 by with DPP4, in RPTEC/TERT1 and HUVEC cells was investigated. For this, an optimized analytical method for increased sensitivity based on LC-MS analysis of chymotrypsin-digested TN-ApoA1 was developed.

**LC-MS analysis of chymotrypsin-digested protein.** Previous methods were based on tryptic or Lys N digest, resulting in the N-terminal peptides APIVNAK or APIVNA, respectively, for the intact TN-ApoA1 molecule. These peptides could be used to monitor the cleavage of AP by analysis of plasma samples taken at different sampling times. However, the corresponding signature peptides IVNAK or IVNA of the catabolite [3-285] could not be monitored due to its low abundance and poor sensitivity of these two short peptides. For this reason, a method was developed based on chymotrypsin digestion, yielding the signature peptides APIVNAKDVKNMKMF for TN-ApoA1 and IVNAKDVKNMKMF for the catabolite [3-285]. Using this refined method, monitoring of the formation of catabolite [3-285] by its key signature peptide IVNAKDVKNMKMF could be achieved in this study.

**Formation of the major catabolite [3-285] of TN-ApoA1 with DPP4.** DPP4, a serine peptidase, cleaves dipetides from the N-terminus of proteins containing A or P in the amino acid two position, XAX or XPX. In case of TN-ApoA1, the N-terminus motif is API, suggesting cleavage by DPP4. Therefore, the biotransformation of TN-ApoA1 by DPP4 was investigated.

After incubation of TN-ApoA1 with DPP4, cleavage of AP to catabolite [3-285] was observed in a time-dependent manner (Fig. 1). Both the disappearance of TN-ApoA1 and the appearance of the catabolite [3-285] could be monitored by intact protein analysis as well as by following specific chymotryptic peptides via LC-MS. In addition, an untargeted search for additional catabolites was performed, but no other catabolites were detected.

![Figure 1. Biotransformation of TN-ApoA1 to [3-285], catalyzed by recombinant DPP4.](https://doi.org/10.1038/s41598-019-40542-5)
Characterization of DPP4 activity in different cell models. After successful demonstration of TN-ApoA1 cleavage by DPP4 to catabolite [3-285], the next aim was to incubate TN-ApoA1 in cellular in vitro models expressing DPP4. Human primary renal proximal tubule epithelial cells (RPTEC/TERT1) and umbilical vein endothelial cells (HUVEC) were investigated as relevant high and low expressing cell lines with respect to DPP4, respectively18,19. In a first step, the selected cellular models were characterized for their DPP4 activity. DPP4 activity was assessed using recombinant human DPP4 as a control, Gly-Pro-AMC as substrate and sitagliptin as DPP4 specific inhibitor (Fig. 2). The determined hydrolysis rates are 24.3 µmol/min/mg, 20.2 nmol/min/mg and 0.58 nmol/min/mg for recombinant human DPP4, RPTEC/TERT1 lysate and HUVEC lysate, respectively. RPTEC/TERT1 lysate had about 35-fold higher hydrolysis activity than HUVEC lysate. In the presence of 2 µM sitagliptin, the hydrolysis activity was almost fully inhibited in the incubates of recombinant human DPP4 and RPTEC/TERT1 lysate; but only 17% inhibition of hydrolysis activity was observed with the HUVEC lysate (Fig. 2B). This indicated that DPP4 was the main enzyme involved in the hydrolysis of Gly-Pro-AMC in RPTEC/TERT1; the hydrolysis activity from HUVEC was not predominantly catalyzed by DPP4, and other hydrolysis enzymes rather than DPP4 hydrolyse the substrate Gly-Pro-AMC. Km values were determined for recombinant human DPP4, RPTEC/TERT1 and HUVEC cell lysates with values of 60 ± 16 µM, 26 ± 2 µM and 47 ± 6 µM determined, respectively (Supplemental Information Fig. 1). The K_m value for recombinant DPP4 was in good agreement with that reported by Mattheussen et al. (58.8 µM)17.

Formation of the major catabolite [3-285] of TN-ApoA1 by RPTEC/TERT1. Formation of the major catabolite [3-285] of TN-ApoA1 by RPTEC/TERT1 and HUVEC was similarly investigated using RPTEC/TERT1. After 4 h of incubation the first traces became visible, and the major catabolite [3-285] increased after 24 h and 48 h of incubation, but remained below 5% of TN-ApoA1 (Fig. 3 and Supplemental Figs 2 and 3). When incubated with HUVEC cells, however, biotransformation was too low to be detectable. This is consistent with the 35-fold lower DPP4 activity in HUVEC cells compared to RPTEC/TERT1 cells.

Discussion
The in vivo biotransformation of lipidated TN-ApoA1 has been described previously16. The formation of the major biotransformation product [3-285] of TN-ApoA1, generated by cleavage of AP at the N-terminus of the sequence, was fast and complete in vivo within 24 h after intravenous administration of TN-ApoA1 to rabbits and also in cynomolgus monkeys and rats. As this biotransformation product is pharmacologically active and therefore conveys most of the pharmacologic effect of TN-ApoA1, it is essential to understand the underlying mechanisms of this biotransformation. DPP4 was thought to be a likely candidate for TN-ApoA1 cleavage, since the fusion protein contains the typical N-terminal recognition sequence Xaa-Pro-Xaa or Xaa-Ala-Xaa12. DPP4 is widely expressed throughout the body, in endothelial cells, including kidney, liver, intestinal brush-border membranes, capillary endothelium, as well as in the vasculature15, enabling it to act as a high capacity biotransformation enzyme for circulating peptides and biologic drugs. The major in vivo biotransformation of TN-ApoA1 could be qualitatively reproduced in a cellular system using the renal proximal tubule epithelial kidney cells RPTEC/TERT1, applying a targeted and highly sensitive detection method based on chymotrypsin digest of TN-ApoA1 and its catabolite [3-285]. This catabolite was also formed to some extent in vitro in plasma from rabbit, rat, Cynomolgus monkey, and man after incubation at room temperature for 24 h16. In HUVEC cells however, where expression of DPP4 is significantly lower than in RPTEC/TERT1, no biotransformation was observed. To our knowledge, this is one of the first reports of an in vitro biotransformation study of a therapeutic protein using cellular models. The reason is most likely because it is experimentally challenging to study the in vitro biotransformation of therapeutic proteins. The major challenges include low biotransformation rate by cells, also in this present case, even though DPP4 is expressed on the cell surface. However, the low in vitro biotransformation rate

Figure 2. A DPP4 catalyzed enzymatic reaction of Gly-Pro-AMC to AMC. B DPP4 activity of recombinant DPP4, RPTEC/TERT1 and HUVEC and DPP4 inhibition by 1 µM Sitagliptin.
Currently significantly limits the application of in vitro biotransformation studies of therapeutic proteins, e.g. for developing predictive clearance tools, or for in vitro drug-drug-interaction assessment. One potential solution to increase the sensitivity would be the application of more sensitive analytical methods, like accelerator mass spectrometry or cavity ring down spectroscopy, however these require 14C labeling of the therapeutic protein. Another potential refinement of the method could be the use of organ-on-a-chip technology with increased incubation times to provide the necessary sensitivity. Nevertheless the information from such experiments is essential to understand and predict species differences, presence of active catabolites and unexpected clearance as well as performance of bioanalytical assays.

In vitro tools for the assessment of mechanisms of biotransformation and other major clearance pathways of therapeutic proteins will enable the estimation of in vivo PK properties, elucidate species differences and help rank multiple compounds early on in research in order to put the most promising candidates into development. A mechanistic understanding of the biotransformation of biotherapeutics and responsible proteolytic enzymes is key also for further compound optimization and stabilization against proteolytic cleavage. Although different mechanisms have to be addressed in the context of biologics disposition, the scope is not comparable to the nowadays widely established tools for early characterization of small molecule disposition. Nevertheless, case studies such as this one will help in the development of a wider knowledge-base from which the biotransformation of biotherapeutics can be assessed in future. This is of especial interest where a biotherapeutic agent is substantially converted to an active catabolite with either therapeutic or toxicological implications.

Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Vugmeyster, Y., Xu, X., Theil, F. P., Khawli, L. A. & Leach, M. W. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 3, 73–92, https://doi.org/10.4331/wjbc.v3.i4.73 (2012).
2. Hamuro, L. L. & Kishnani, N. S. Metabolism of biologics: biotherapeutic proteins. Bioanalysis 4, 189–195, https://doi.org/10.4155/bio.11.304 (2012).
3. Hall, M. P. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling. Drug Metab Dispos 42, 1873–1880, https://doi.org/10.1124/dmd.114.058347 (2014).
4. Hall, M. P. et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. Aaps J 12, 576–585, https://doi.org/10.1208/s12248-010-9218-9 (2010).
5. Liu, Y. D., van Enk, J. Z. & Flynn, G. C. Human antibody Fc deamidation in vivo. Biologicals 37, 313–322, https://doi.org/10.1016/j.biologicals.2009.06.001 (2009).
6. Liu, Y. D., Goetze, A. M., Bass, R. B. & Flynn, G. C. N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem 286, 11211–11217, https://doi.org/10.1074/jbc.M110.185041 (2011).
7. Zhang, D. et al. Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates. Drug Metab Dispos 44, 1517–1523, https://doi.org/10.1124/dmd.116.070631 (2016).
8. Butts, P., Bischoff, R., Bakker, H., Gietema, J. A. & van de Merbel, N. C. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem 88, 1871–1877, https://doi.org/10.1021/acs.analchem.5b04276 (2016).
9. Cai, B., Pan, H. & Flynn, G. C. C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng 108, 404–412, https://doi.org/10.1002/bit.23933 (2011).
10. Werle, M. & Bernkop-Schnürch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351–367, https://doi.org/10.1007/s00726-005-0289-3 (2006).
11. Deacon, C. F. Circulation and degradation of GIP and GLP-1. Horm Metab Res 36, 761–765, https://doi.org/10.1055/s-2004-826160 (2004).
12. Mentlein, R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept 85, 9–24 (1999).
13. Sharma, R. et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos 41, 2148–2157, https://doi.org/10.1124/dmd.113.054254 (2013).
14. Zvereva, I., Semenistaya, E., Krotov, G. & Rodchenkov, G. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteomics 149, 85–97, https://doi.org/10.1016/j.jprot.2016.08.016 (2016).
15. Radchenko, T. et al. Software-aided approach to investigate peptide structure and metabolic susceptibility of amide bonds in peptide drugs based on high resolution mass spectrometry. Plos one 12, e0186461, https://doi.org/10.1371/journal.pone.0186461 (2017).
16. Zell, M. et al. In Vivo Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by ELISA. Anal Chem 88, 11670–11677, https://doi.org/10.1021/acs.analchem.6b03252 (2016).
17. Matheussen, V. et al. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 413, 456–462, https://doi.org/10.1016/j.cca.2011.10.031 (2012).
18. Protein Atlas version 18.1, https://www.proteinatlas.org/ENSG00000197635-DPP4/cell (2018).
19. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 413–419, https://doi.org/10.1126/science.1260419 (2015).
20. Kratochwil, N. A. et al. Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies. Plos one 16, e0205435, https://doi.org/10.1371/journal.pone.0205435 (2018).

Acknowledgements
The RPTEC/TERT1 cells (Evercyte GmbH, CHT-003-002) were kindly provided by Laurence Hilfiger and Dr. Marcel Gübler.

Author Contributions
Study was planned by S.S., R.F.S., C.H., A.E., N.H.Q., S.F. and N.A.K. Experiments were conducted by C.H., A.E and N.H.Q. Data was analyzed and interpreted by S.S., R.F.S., C.H., A.E., N.H.Q., S.F. and N.A.K. The manuscript was written by S.S., S.F., C.H., A.E and N.H.Q. All authors have given approval to the final version of the manuscript.

Additional Information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41598-019-40542-5.

Competing Interests: All authors are employees of F. Hoffmann-La Roche Ltd.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.